<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252810</url>
  </required_header>
  <id_info>
    <org_study_id>GE 145-002</org_study_id>
    <nct_id>NCT01252810</nct_id>
  </id_info>
  <brief_title>Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Statprobe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rules-Based Medicine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when
      compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either
      chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive
      heart failure (CHF) NYHA Class III or greater, who are referred for a coronary
      catheterization procedure with or without PCI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.</measure>
    <time_frame>After the imaging date for either Ioforminol or Iopamidol.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration</measure>
    <time_frame>Time zero equals the date of contrast imaging and for up to 7 days for safety monitoring post contrast administration.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol.
To determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol.
Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections</measure>
    <time_frame>2, 6 and 24 hours post Ioforminol and Iopamidol adminstration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Cardio Renal Safety in High-risk Elderly Subjects Undergoing a Coronary CATH With or Without PCI.</condition>
  <arm_group>
    <arm_group_label>GE 145 320mg I/ml injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopamidol 370mg I/ml injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GE-145</intervention_name>
    <description>GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.</description>
    <arm_group_label>GE 145 320mg I/ml injection</arm_group_label>
    <arm_group_label>Iopamidol 370mg I/ml injection</arm_group_label>
    <other_name>Ioforminol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 65 years of age with cardiovascular disease who are referred for a
             coronary catheterization procedure with or without PCI.

          -  The subject has at least one of the following comorbidities:

          -  1) Chronic renal insufficiency, (eGFR &lt;60 but 15 mL/min/1.73 m2 according to the MDRD
             equation) as measured within 2 weeks or at the screening visit;

          -  2) DM diagnosed greater than 6 months prior to study entry and which requires either
             insulin or anti-hyperglycemic drug therapy;

          -  3) CHF (NYHA) class III or greater measured within 2 weeks of enrollment or at the
             screening visit.

        Exclusion Criteria:

          -  The subject has known allergies to either iodine or any ICM.

          -  The subject has severe renal insufficiency (eGFR &lt;15 mL/min/1.73 m2 according to the
             MDRD equation) or is on dialysis.

          -  The subject has acute coronary syndrome requiring emergency coronary angiography
             and/or intervention.

          -  The subject is not willing or unable to discontinue metformin (e.g., Glucophage) at
             the time of the study procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubin Sheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>December 1, 2010</firstreceived_date>
  <firstreceived_results_date>February 6, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CATH Catheterization</keyword>
  <keyword>CI-AKI Contrast-induced acute kidney injury</keyword>
  <keyword>DM Diabetes mellitus</keyword>
  <keyword>eGFR Estimated glomerular filtration rate</keyword>
  <keyword>MDRD Modification of Diet in Renal Disease</keyword>
  <keyword>NYHA New York Heart Association</keyword>
  <keyword>PCI Percutaneous coronary intervention</keyword>
  <keyword>SCr Serum creatinine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iopamidol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ioforminol 320mg I/ml Injection</title>
          <description>Ioforminol 320 mg I/mL as a single iv. administration.</description>
        </group>
        <group group_id="P2">
          <title>Iopamidol 370mg I/ml Injection</title>
          <description>Iopamidol 370 mg I/mL as a single iv. administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various reasons</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ioforminol 320mg I/ml Injection</title>
          <description>Ioforminol 320 mg I/mL as a single iv. administration.</description>
        </group>
        <group group_id="B2">
          <title>Iopamidol 370mg I/ml Injection</title>
          <description>Iopamidol 370 mg I/mL as a single iv. administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="141"/>
                <measurement group_id="B3" value="278"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Per a Protocol Amendment, A-01, the minimum age changed to male or female greater than or equal to 18 years of age who have a history of chronic renal insufficiently.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="111"/>
                <measurement group_id="B3" value="220"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="101"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="177"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="128"/>
                <measurement group_id="B2" value="134"/>
                <measurement group_id="B3" value="262"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.</title>
        <description>Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.</description>
        <time_frame>After the imaging date for either Ioforminol or Iopamidol.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The measured values are looking at 1) Overall Image Quality and, 2) Diagnostic Usefulness.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioforminol 320mg I/ml Injection</title>
            <description>Ioforminol 320 mg I/mL as a single iv. administration.</description>
          </group>
          <group group_id="O2">
            <title>Iopamidol 370mg I/ml Injection</title>
            <description>Iopamidol 370 mg I/mL as a single iv. administration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.</title>
            <description>Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales.</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall Image Quality-Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall Image Quality-Adequate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overal Image Quality-Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diagnostic Usefulness-Diagnostic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="134"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diagnostic Usefulness-Non-Diagnostic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration</title>
        <description>To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol.
To determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol.
Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.</description>
        <time_frame>Time zero equals the date of contrast imaging and for up to 7 days for safety monitoring post contrast administration.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioforminol 320mg I/ml Injection</title>
            <description>Ioforminol 320 mg I/mL as a single iv. administration.</description>
          </group>
          <group group_id="O2">
            <title>Iopamidol 370mg I/ml Injection</title>
            <description>Iopamidol 370 mg I/mL as a single iv. administration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration</title>
            <description>To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol.
To determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol.
Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects.</description>
            <units>Number of events</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Angina Pectoris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Coronary Artery Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Catheter-Site Hematoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Catheter-Site Hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Catheter-Site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urinary Tract Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Creatinine Increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain In Extremity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dizziness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections</title>
        <description>Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI).</description>
        <time_frame>2, 6 and 24 hours post Ioforminol and Iopamidol adminstration</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Summary of subjects with renal biomarker-based CI-AKI by time point (Per Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Ioforminol 320mg I/ml Injection</title>
            <description>Ioforminol 320 mg I/mL as a single iv. administration.</description>
          </group>
          <group group_id="O2">
            <title>Iopamidol 370mg I/ml Injection</title>
            <description>Iopamidol 370 mg I/mL as a single iv. administration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections</title>
            <description>Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Time- Post Contrast, 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Time- Post Contrast, 6 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Time- Post Contrast, 24 hourss</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days post Ioforminol and Iopamidol administrations.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ioforminol 320mg I/ml Injection</title>
          <description>Ioforminol 320 mg I/mL as a single iv. administration. Up to 7 days post Iopamidol administration.</description>
        </group>
        <group group_id="E2">
          <title>Iopamidol 370mg I/ml Injection</title>
          <description>Iopamidol 370 mg I/mL as a single iv. administration. Up to 7 days post Ioforminol administration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Congestive cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Coronary artery disease and hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm to hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion to hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter-Site Hemotoma</sub_title>
                <description>Site of Administration</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruben Sheng, M.D.</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>609-514-6899</phone>
      <email>Rubin.Sheng@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
